1. New Perspectives in CAD and PAD: Weighing the Latest Evidence

3. Program Goals

4. Burden of CAD and PAD

5. REACH Registry

6. REACH Registry Economic Burden of PAD in the United States

7. Management of CAD and PAD Antithrombotic Strategies

8. CURE Dual Antiplatelet Therapy in Non-STE ACS

9. Dual Antiplatelet Strategies in CAD

10. Anticoagulant Therapy in CAD Warfarin -- WARIS-2

11. Warfarin + Aspirin after MI or ACS Meta-Analysis

12. Warfarin + Aspirin After ACS Meta-Analysis

13. Anticoagulant Therapy With NOACs in CAD Apixaban -- APPRAISE-2

14. Rivaroxaban ATLAS ACS-TIMI 46 -- Clinically Significant Bleeding

15. Rivaroxaban ATLAS ACS-TIMI 46 -- Efficacy Outcomes

16. Rivaroxaban: ATLAS ACS 2-TIMI 51

17. Rivaroxaban ATLAS ACS 2-TIMI 51-- Primary Efficacy Outcome

18. Rivaroxaban ATLAS ACS 2-TIMI 51 -- Bleeding Outcomes

19. Rivaroxaban COMPASS -- Trial Design

20. Rivaroxaban COMPASS -- Trial Design (cont)

21. COMPASS Efficacy Outcomes

22. COMPASS Bleeding Outcomes and Net Clinical Benefit

23. COMPASS PAD MALE and Major Amputation

24. Lessons Learned

25. Holistic Approach to Management

26. Tailoring Therapy

27. Summary

28. Abbreviations

29. Abbreviations (cont)